AC Immune (ACIU) Expected to Announce Quarterly Earnings on Tuesday

AC Immune (NASDAQ:ACIU) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect AC Immune to post earnings of $0.1214 per share and revenue of $34.0840 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 12:30 PM ET.

AC Immune Stock Performance

NASDAQ ACIU opened at $2.19 on Monday. AC Immune has a 1 year low of $2.03 and a 1 year high of $4.00. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.87 and a quick ratio of 1.02. The firm has a market cap of $222.88 million, a price-to-earnings ratio of -2.67 and a beta of 1.59. The company has a fifty day moving average price of $2.42 and a 200-day moving average price of $2.81.

Wall Street Analyst Weigh In

ACIU has been the topic of several analyst reports. Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research note on Monday, May 4th. Finally, HC Wainwright reiterated a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.50.

Insider Activity at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $2.79, for a total transaction of $27,900.00. Following the transaction, the chief executive officer owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. This represents a 0.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AC Immune

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EFG International AG purchased a new stake in AC Immune during the fourth quarter valued at about $41,000. Private Advisor Group LLC purchased a new position in shares of AC Immune in the third quarter worth about $48,000. Sei Investments Co. bought a new stake in shares of AC Immune in the second quarter valued at approximately $51,000. Goldman Sachs Group Inc. raised its position in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares during the period. Finally, Susquehanna International Group LLP purchased a new stake in shares of AC Immune during the 3rd quarter valued at approximately $63,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.